University of Pennsylvania — Assistant Professor of Laboratory Animal Medicine, AC track, Department of Pathobiology : The Journal of Blacks in Higher Education jbhe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jbhe.com Daily Mail and Mail on Sunday newspapers.
Coronavirus vaccine trials: Bharat Biotech said that it is steadily moving towards its goal of 26,000 volunteers. Phase 3 of human clinical trials for Covaxin began in mid-November
COVID-19: Bharat Biotech recruits 23,000 volunteers for COVAXIN s phase 3 clinical trial ANI | Updated: Jan 02, 2021 22:36 IST
Hyderabad (Telangana) [India], January 2 (ANI): Bharat Biotech has recruited 23,000 volunteers so far for the Phase III clinical trials of its COVID-19 vaccine candidate, COVAXIN . Bharat Biotech has announced successful recruitment of 23,000 volunteers, and continued progress towards achieving the goal of 26,000 participants for Phase-3 clinical trial of coronavirus vaccine COVAXIN across multiple sites in India, an official statement read.
COVAXIN, India s indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). This indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech s BSL-3 (Bio-Safety Level 3) bio-containment facility, one of its kind in the world.
Coronavirus vaccine India | Bharat Biotech successfully recruits 23,000 volunteers across India
The company will now look to towards achieving the goal of 26,000 participants for Phase-3 clinical trial of COVAXIN across multiple sites in India. January 02, 2021 / 10:22 PM IST
Hyderabad-based Bharat Biotech, which is developing an indigenous COVID-19 vaccine candidate said it has successfully recruited 23,000 volunteers on January 2.
It will now look to towards achieving the goal of 26,000 participants for Phase-3 clinical trial of COVAXIN across multiple sites in India.
What is COVAXIN?
COVAXIN is a highly purified and inactivated 2 dose SARS-CoV2 vaccine. It is manufactured in a Vero cell manufacturing platform and currently has a safety track record of more than 300 million doses, according to a release.
Published: Dec 21, 2020
Autobahn Labs and UCSF will establish new ventures for drug discovery and development
PALO ALTO, Calif. and SAN FRANCISCO, Dec. 21, 2020 /PRNewswire/
Autobahn Labs, a virtual incubator partnering with top academic and research institutions to catalyze early-stage drug discovery and development, today announced a strategic collaboration with the
University of California San Francisco (UCSF). The organizations will partner to identify promising early science with significant therapeutic potential, forming jointly owned ventures to accelerate the translation of scientific ideas to novel therapeutics. UCSF combines world-class medicine, cutting-edge research, and a strong track record of innovation in drug discovery, said Thomas Novak, PhD, Chief Scientific Officer of Autobahn Labs. We re excited to partner their great science with Autobahn Labs resources and capabilities to spark the development of meaningful new therapies for patients.